Effect of essential amino acid кetoanalogues and protein restriction diet on morphogenetic proteins (FGF-23 and Кlotho) in 3b–4 stages chronic кidney disease patients: a randomized pilot study
- 10 Downloads
A low protein diet (LPD) with essential amino acid ketoanalogue supplementation (KA) may contribute in improving of chronic kidney disease (CKD), while the exact mechanisms of KA’s effect are not established yet. We have conducted a prospective, randomized, controlled comparative study of LPD + KA and LPD alone in relation to serum Klotho, FGF-23 levels in CKD patients.
79 non-diabetic CKD 3b–4 stage patients, compliant with LPD diet (0.6 g/kg of body weight/day), had been selected. The patients were randomized into two groups. The first group (42 patients) received LPD + КA. The second group (37 patients) continued the LРD alone. In addition to routine tests, serum Klotho, FGF-23 levels, as well as bioimpedance analysis, sphygmography (stiffness (augmentation) indices (AI), central (aortal) blood pressure) with a «SphygmaCor» device; echocardiography (valvular calcification score (VCS) and LVMMI), were performed.
There were body mass indices’ decrease (p = 0.046), including muscle body mass in men (p = 0.027) and woman (p = 0.044) in the LPD group to the end of study (14th month). In addition, lower FGF-23 (p = 0.029), and higher sKlotho (p = 0.037) were detected in the LPD + KA group compared to the LPD one. The increase in AI (p = 0.034), VCS (p = 0.048), and LVMMI (p = 0.023) was detected more often in the LPD group at the end of study.
LPD + KA provides support for nutrition status and contributes to more efficient correction of FGF-23 and Klotho abnormalities that may result in cardiovascular calcification and cardiac remodeling decreasing in CKD. At the same time, a prolonged LPD alone may lead to malnutrition.
KeywordsChronic kidney disease Essential amino acid ketoanalogues Fibroblast growth factor-23 (FGF-23) Serum alpha-Klotho (sKlotho) Cardiovascular calcification Cardiac remodeling
This work was supported by the Russian Science Foundation (Grant No. 14-15-00947 2014).
Compliance with ethical standards
The study was approved by the Institutional Review Board of the Sechenov First Moscow State Medical University (Protocol No. 06–14, 16.06.2014). All the patients provided written informed consent. All the described procedures were performed in accordance with the Helsinki Declaration.
- 18.Hu MC, Shiizaki K, Kuro-O M, Moe OW. Fibroblast growth factor 23 and klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol. 2013. p. 503–33. https://doi.org/10.1146/annurev-physiol-030212-183727.
- 19.Neyra JA, Hu MC. αKlotho and chronic kidney disease. Vitam Horm. 2016. p. 257–310. https://doi.org/10.1016/bs.vh.2016.02.007.
- 27.Ermolenko VM, Volgina GV, Dobronravov VA, et al. National recommendations on mineral and bone disorders in chronic kidney disease. Russian Dialysis Society (May 2010).Nephrologia I Dialis. 2011;13(1):33–51.Google Scholar
- 33.NasrAllah MM, El-Shehaby AR, Osman NA, Fayad T, Nassef A, Salem MM, et al. The association between fibroblast growth factor-23 and vascular calcification is mitigated by inflammation markers. Nephron Extra. 2013;3(1):106–12. https://doi.org/10.1159/000356118.CrossRefPubMedPubMedCentralGoogle Scholar